Return to intended oncologic treatment (RIOT): A novel metric for evaluating the quality of oncosurgical therapy for malignancy

Journal of Surgical Oncology

Volumn 110, Issue 2, 2014, Pages 107-114

  Aloia, Thomas A ^a   Zimmitti, Giuseppe ^a   Conrad, Claudius ^a   Gottumukalla, Vijaya ^a   Kopetz, Scott ^a   Vauthey, Jean Nicolas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

adjuvant therapy; colorectal liver metastases; minimally invasive surgery; outcomes; surgical oncology

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; COMORBIDITY; DISEASE FREE SURVIVAL; FEMALE; HEALTH CARE QUALITY; HOSPITALIZATION; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MINIMALLY INVASIVE SURGERY; ONCOLOGICAL PARAMETERS; OPERATIVE BLOOD LOSS; OVERALL SURVIVAL; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETURN TO INTENDED ONCOLOGIC TREATMENT; RISK FACTOR; TREATMENT OUTCOME;

ADJUVANT THERAPY; COLORECTAL LIVER METASTASES; MINIMALLY INVASIVE SURGERY; OUTCOMES; SURGICAL ONCOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; POSTOPERATIVE COMPLICATIONS; QUALITY INDICATORS, HEALTH CARE; RETROSPECTIVE STUDIES; RISK FACTORS; SURGICAL PROCEDURES, MINIMALLY INVASIVE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84903119990     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23626     Document Type: Article

References (38)

1. Bowater RJ, Abdelmalik SM, Lilford RJ,: Efficacy of adjuvant chemotherapy after surgery when considered over all cancer types: A synthesis of meta-analyses. Ann Surg Oncol 2012; 19: 3343-3350.
2. Kopetz S, Chang GJ, Overman MJ, et al.: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-3683.
3. Adam R, De Gramont A, Figueras J, et al.: The oncosurgery approach to managing liver metastases from colorectal cancer: A multidisciplinary international consensus. Oncologist 2012; 17: 1225-1239.
4. Choti MA, Sitzmann JV, Tiburi MF, et al.: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235: 759-766. (Pubitemid 34547293)
5. Fernandez FG, Drebin JA, Linehan DC, et al.: Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240: 438-447.
6. D'Angelica M, Kornprat P, Gonen M, et al.: Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Ann Surg Oncol 2011; 18: 1096-1103.
7. Fong Y, Cohen AM, Fortner JG, et al.: Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938-946. (Pubitemid 27106275)
8. Petrelli NJ,: Perioperative or adjuvant therapy for resectable colorectal hepatic metastases. J Clin Oncol 2008; 26: 4862-4863.
9. Nakajima Y, Nagao M, Ko S, et al.: Clinical predictors of recurrence site after hepatectomy for metastatic colorectal cancer. Hepatogastroenterology 2001; 48: 1680-1684. (Pubitemid 34003503)
10. Allegra CJ, Yothers G, O'Connell MJ, et al.: Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08. J Clin Oncol 2011; 29: 11-16.
11. de Jong MC, Pulitano C, Ribero D, et al.: Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: An international multi-institutional analysis of 1669 patients. Ann Surg 2009; 250: 440-448.
12. Madoff DC, Abdalla EK, Gupta S, et al.: Transhepatic ipsilateral right portal vein embolization extended to segment IV: Improving hypertrophy and resection outcomes with spherical particles and coils. J Vasc Interv Radiol 2005; 16: 215-225. (Pubitemid 40322294)
13. Shindoh J, Truty MJ, Aloia TA, et al.: Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: Toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg 2013; 216: 201-209.
14. Chang SB, Palavecino M, Wray CJ, et al.: Modified Makuuchi incision for foregut procedures. Arch Surg 2010; 145: 281-284.
15. Aloia TA, Zorzi D, Abdalla EK, et al.: Two-surgeon technique for hepatic parenchymal transection of the noncirrhotic liver using saline-linked cautery and ultrasonic dissection. Ann Surg 2005; 242: 172-177. (Pubitemid 41033432)
16. Belghiti J, Clavien PA, Gadzijev E, et al.: The Brisbane 2000 terminology of liver anatomy and resections. HPB 2000; 2: 333-339. (Pubitemid 32185922)
17. Zimmitti G, Roses RE, Andreou A, et al.: Greater complexity of liver surgery is not associated with an increased incidence of liver-related complications except for bile leak: An experience with 2,628 consecutive resections. J Gastrointest Surg 2013; 17: 57-64. discussion 64-55.
18. Dindo D, Demartines N, Clavien PA,: Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213. (Pubitemid 38963009)
19. O'Connell MJ, Adson MA, Schutt AJ, et al.: Clinical trial of adjuvant chemotherapy after surgical resection of colorectal cancer metastatic to the liver. Mayo Clin Proc 1985; 60: 517-520. (Pubitemid 16241712)
20. Lopez-Ladron A,: Observation versus postoperative chemotherapy after resection of liver metastases in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2003; 22: 373.
21. Langer B,: (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): Results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol 2002; 21: 149a.
22. Portier G, Elias D, Bouche O, et al.: Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976-4982. (Pubitemid 46631399)
23. Mitry E, Fields AL, Bleiberg H, et al.: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: A pooled analysis of two randomized trials. J Clin Oncol 2008; 26: 4906-4911.
24. Parks R, Gonen M, Kemeny N, et al.: Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: Analysis of data from two continents. J Am Coll Surg 2007; 204: 753-761. discussion 761-753. (Pubitemid 46661187)
25. Fong Y, Fortner J, Sun RL, et al.: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318.
26. Figueras J, Torras J, Valls C, et al.: Surgical resection of colorectal liver metastases in patients with expanded indications: A single-center experience with 501 patients. Dis Colon Rectum 2007; 50: 478-488. (Pubitemid 46701611)
27. Wang X, Hershman DL, Abrams JA, et al.: Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br J Cancer 2007; 97: 1606-1612. (Pubitemid 350249362)
28. Kim SY, Kim HJ, Hong YS, et al.: Resected colorectal liver metastases: Does the survival differ according to postoperative chemotherapy regimen ? J Surg Oncol 2009; 100: 713-718.
29. Ychou M, Hohenberger W, Thezenas S, et al.: A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009; 20: 1964-1970.
30. Aloia TA, Lee JE, Vauthey JN, et al.: Delayed recovery after pancreaticoduodenectomy: A major factor impairing the delivery of adjuvant therapy ? J Am Coll Surg 2007; 204: 347-355. (Pubitemid 46283494)
31. Merkow RP, Bilimoria KY, Tomlinson JS, et al.: Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg 2013; [Epub ahead of print].
32. Aloia T, Sebagh M, Plasse M, et al.: Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24: 4983-4990. (Pubitemid 46631400)
33. Vauthey JN, Pawlik TM, Ribero D, et al.: Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072. (Pubitemid 46622116)
34. Kopetz S, Vauthey JN,: Perioperative chemotherapy for resectable hepatic metastases. Lancet 2008; 371: 963-965. (Pubitemid 351389517)
35. Bonadonna G, Moliterni A, Zambetti M, et al.: 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: Cohort study. BMJ 2005; 330: 217.
36. Bonadonna G, Valagussa P,: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981; 304: 10-15. (Pubitemid 11212891)
37. Weycker D, Barron R, Edelsberg J, et al.: Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. Breast Cancer Res Treat 2012; 133: 301-310.
38. Kwak LW, Halpern J, Olshen RA, et al.: Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 1990; 8: 963-977. (Pubitemid 20200184)